The Onkimmune Team

CEO: MARK PHILIP, PHD, MBA

    • 25 years experience in the Biopharma and Medical Device Industry.
    • President, CEO, Board, GM roles in: Baxter International, Immuno-­‐U.S.., Stryker, Zycos, BBI, Znomics
    • Boston University MBA Program Faculty

michael O'DwyerFOUNDER & CSO: MICHAEL O’DWYER, MD

    • Professor of Hematology, National University of Ireland, Galway.
    • HRB Clinician Scientist
    • Director SFI Blood Cancer Network Ireland
    • Former Assistant Professor at Oregon Health & Sciences University: worked on development of imatinib
    • Member of the International Myeloma Working Group (IMWG)

Scientific Advisory Board

Armand Keating BSc., FRCSC, FRCPC, MD.,
University of Toronto

  • Scientist, Krembil Research Institute (Krembil)
  • Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
  • Director, Philip S. Orsino Cell Therapy Translational Research
  • Laboratory, Princess Margaret Hospital
  • Director, Cell Therapy Program, Princess Margaret Hospital
  • Professor of Medicine, University of Toronto
  • Professor, Institute of Biomaterials and Biomedical Engineering, University of Toronto
  • Full Member, Institute of Medical Science, University of Toronto

Jeffery Miller MD
University of Minnesota

  • Professor of Medicine, Division of Hematology, Oncology and Transplantation
  • Deputy Director, Masonic Cancer Center (MCC)
  • Roger L. and Lynn C. Headrick Chair in Cancer Therapeutics
  • Associate Scientific Director, Molecular and Cellular Therapeutics
  • Professor, Microbiology, Immunology and Cancer Biology (MICaB) Ph.D. Graduate Program

Malcolm Brenner MD, PHD.
Baylor College of Medicine

  • Professor, Center for Cell and Gene Therapy
  • Professor, Molecular and Human Genetics
  • Professor, Pediatrics
  • Professor, Medicine
  • Professor, Program in Translational Biology & Molecular Medicine
  • Fayez Sarofim Chair
  • Member, Executive Committee, Dan L Duncan Comprehensive Cancer Center

Collaborators

Rick Childs
TRAILv (NIH)

Tuna Mutis
VUmc Amsterdam

Jinsong Hu
Xi’an Jiaotong University

0
2nd (Cause of death globally – 1 in 6 deaths are due to cancer)1
0
Billion $ (the global oncology market by 2022)
0
$1.2 Trillion (Economic cost of cancer today)1
0
100 (there are over 100 types of cancer)1

1 http://www.who.int/news-room/fact-sheets/detail/cancer
2 https://www.iqvia.com/institute/reports/global-oncology-trends-2018
3 https://www.cancer.gov/types